Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Prodrugs site-specific drug release

In the design of drugs, the usefulness of renal-specific enzymes which enable the site-specific release of the active drug, should be taken into account. The design of kidney-selective prodrugs is based upon the relatively higher amounts of certain enzymes in the proximal tubular cells than elsewhere in the body. [Pg.132]

Figure 16.2 Dihydropyridine-pyridinium salt redox system for site-specific and sustained delivery to the brain. The prodrug A is delivered directly to the brain, where it is oxidized and trapped as the prodrug B. The quaternary ammonium salt is slowly cleaved by chemical/enzymatic action with sustained release of the biologically active phenylethylamine C and the facile elimination of the carrier molecule D. Elimination of the drug from the general circulation is by comparison accelerated, either as A or B or as cleavage products... Figure 16.2 Dihydropyridine-pyridinium salt redox system for site-specific and sustained delivery to the brain. The prodrug A is delivered directly to the brain, where it is oxidized and trapped as the prodrug B. The quaternary ammonium salt is slowly cleaved by chemical/enzymatic action with sustained release of the biologically active phenylethylamine C and the facile elimination of the carrier molecule D. Elimination of the drug from the general circulation is by comparison accelerated, either as A or B or as cleavage products...
An interesting example of the above difference is l-DOPA 4, which is used in the treatment of Parkinson s disease. The active drug is the achiral compound dopamine formed from 4 via in vivo decarboxylation. As dopamine cannot cross the blood-brain barrier to reach the required site of action, the prodrug 4 is administered. Enzyme-catalyzed in vivo decarboxylation releases the drug in its active form (dopamine). The enzyme l-DOPA decarboxylase, however, discriminates the stereoisomers of DOPA specifically and only decarboxylates the L-enantiomer of 4. It is therefore essential to administer DOPA in its pure L-form. Otherwise, the accumulation of d-DOPA, which cannot be metabolized by enzymes in the human body, may be dangerous. Currently l-DOPA is prepared on an industrial scale via asymmetric catalytic hydrogenation. [Pg.6]


See other pages where Prodrugs site-specific drug release is mentioned: [Pg.728]    [Pg.568]    [Pg.411]    [Pg.341]    [Pg.210]    [Pg.728]    [Pg.179]    [Pg.519]    [Pg.192]    [Pg.229]    [Pg.596]    [Pg.195]    [Pg.199]    [Pg.729]    [Pg.833]    [Pg.511]    [Pg.1381]    [Pg.124]    [Pg.570]    [Pg.666]    [Pg.411]    [Pg.413]    [Pg.729]    [Pg.833]    [Pg.115]    [Pg.441]    [Pg.136]    [Pg.263]    [Pg.247]    [Pg.39]    [Pg.263]    [Pg.23]    [Pg.23]    [Pg.73]    [Pg.1391]    [Pg.1393]    [Pg.201]    [Pg.224]    [Pg.119]    [Pg.479]    [Pg.143]    [Pg.203]    [Pg.509]    [Pg.588]    [Pg.114]    [Pg.336]    [Pg.112]   


SEARCH



Drug release

Drug release site-specific

Prodrug

Prodrugs site specific

Release specifications

Site specificity

Specific Drugs

© 2024 chempedia.info